Amiodarone Drug Interactions
298Total Interactions
177Severe
39Moderate
1Mild
| Drug | Severity | Summary |
|---|---|---|
| Acebutolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Ac... |
| Acenocoumarol | SEVERE | Amiodarone increases the anticoagulant effect of Acenocoumarol. Manufacturer advises monitor INR. |
| Alcohol | SEVERE | Alcohol -induced liver disease increases the risk of hepatotoxicity in those taking Amiodarone. M... |
| Aliskiren | SEVERE | Amiodarone is predicted to increase the exposure to Aliskiren. Manufacturer advises caution. |
| Amifampridine | SEVERE | Both Amiodarone and Amifampridine prolong the QT interval. Most manufacturers advise avoiding the... |
| Aminophylline | SEVERE | Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Amisulpride | SEVERE | Both Amiodarone and Amisulpride prolong the QT interval. Most manufacturers advise avoiding the u... |
| Amphotericin B | SEVERE | Amphotericin B is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Anagrelide | SEVERE | Both Amiodarone and Anagrelide prolong the QT interval. Most manufacturers advise avoiding the us... |
| Apalutamide | SEVERE | Both Amiodarone and Apalutamide prolong the QT interval. Most manufacturers advise avoiding the u... |
| Apomorphine | SEVERE | Both Amiodarone and Apomorphine prolong the QT interval. Most manufacturers advise avoiding the u... |
| Aripiprazole | SEVERE | Both Amiodarone and Aripiprazole prolong the QT interval. Most manufacturers advise avoiding the ... |
| Arsenic trioxide | SEVERE | Both Amiodarone and Arsenic trioxide prolong the QT interval. Most manufacturers advise avoiding ... |
| Artemether | SEVERE | Both Amiodarone and Artemether prolong the QT interval. Most manufacturers advise avoiding the us... |
| Artenimol | SEVERE | Both Amiodarone and Artenimol prolong the QT interval. Most manufacturers advise avoiding the use... |
| Atazanavir | SEVERE | Atazanavir is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Atenolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with At... |
| Beclometasone | SEVERE | Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Bedaquiline | SEVERE | Both Amiodarone and Bedaquiline prolong the QT interval. Most manufacturers advise avoiding the u... |
| Bemiparin | SEVERE | Amiodarone might increase the risk of hepatotoxicity when given with Bemiparin (high-dose). Manuf... |
| Bendroflumethiazide | SEVERE | Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Betamethasone | SEVERE | Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Betaxolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Be... |
| Bisoprolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Bi... |
| Bosutinib | SEVERE | Both Amiodarone and Bosutinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Brentuximab vedotin | SEVERE | Amiodarone is predicted to increase the risk of neutropenia when given with Brentuximab vedotin. ... |
| Budesonide | SEVERE | Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Bumetanide | SEVERE | Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Cabozantinib | SEVERE | Both Amiodarone and Cabozantinib prolong the QT interval. Most manufacturers advise avoiding the ... |
| Carvedilol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Ca... |
| Celiprolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Ce... |
| Ceritinib | SEVERE | Both Amiodarone and Ceritinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Chloroprocaine | SEVERE | Chloroprocaine is predicted to increase the risk of cardiovascular adverse effects when given wit... |
| Chlorothiazide | SEVERE | Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Chlorpromazine | SEVERE | Both Amiodarone and Chlorpromazine prolong the QT interval. Most manufacturers advise avoiding th... |
| Chlortalidone | SEVERE | Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Ciclosporin | SEVERE | Amiodarone increases the concentration of Ciclosporin. Manufacturer advises monitor concentration... |
| Citalopram | SEVERE | Both Amiodarone and Citalopram prolong the QT interval. Most manufacturers advise avoiding the us... |
| Clomipramine | SEVERE | Both Amiodarone and Clomipramine prolong the QT interval. Most manufacturers advise avoiding the ... |
| Cobicistat | SEVERE | Cobicistat potentially increases the concentration of Amiodarone. Manufacturer makes no recommend... |
| Colchicine | SEVERE | Amiodarone is predicted to increase the exposure to Colchicine. Manufacturer advises avoid P-glyc... |
| Crizotinib | SEVERE | Both Amiodarone and Crizotinib prolong the QT interval. Most manufacturers advise avoiding the us... |
| Dabigatran | SEVERE | Amiodarone increases the exposure to Dabigatran. Manufacturer advises monitor and adjust dose. |
| Dalteparin | SEVERE | Amiodarone might increase the risk of hepatotoxicity when given with Dalteparin (high-dose). Manu... |
| Darunavir | SEVERE | Darunavir is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Dasatinib | SEVERE | Both Amiodarone and Dasatinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Deflazacort | SEVERE | Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Delamanid | SEVERE | Both Amiodarone and Delamanid prolong the QT interval. Most manufacturers advise avoiding the use... |
| Desflurane | SEVERE | Both Amiodarone and Desflurane prolong the QT interval. Most manufacturers advise avoiding the us... |
| Dexamethasone | SEVERE | Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Digoxin | SEVERE | Amiodarone is predicted to moderately increase the exposure to Digoxin. Manufacturer advises moni... |
| Diltiazem | SEVERE | Amiodarone is predicted to increase the risk of cardiodepression when given with Diltiazem. Manuf... |
| Domperidone | SEVERE | Domperidone increases the risk of QT-prolongation when given with Amiodarone. Manufacturer advise... |
| Droperidol | SEVERE | Both Amiodarone and Droperidol prolong the QT interval. Most manufacturers advise avoiding the us... |
| Edoxaban | SEVERE | Amiodarone slightly increases the exposure to Edoxaban. Manufacturer makes no recommendation. |
| Efavirenz | SEVERE | Both Amiodarone and Efavirenz prolong the QT interval. Most manufacturers advise avoiding the use... |
| Encorafenib | SEVERE | Both Amiodarone and Encorafenib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Enoxaparin | SEVERE | Amiodarone might increase the risk of hepatotoxicity when given with Enoxaparin (high-dose). Manu... |
| Entrectinib | SEVERE | Both Amiodarone and Entrectinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Eplerenone | SEVERE | Amiodarone is predicted to increase the exposure to Eplerenone. Manufacturer advises adjust Epler... |
| Erdafitinib | SEVERE | Amiodarone is predicted to increase the exposure to Erdafitinib. Manufacturer advises adjust dose. |
| Eribulin | SEVERE | Both Amiodarone and Eribulin prolong the QT interval. Most manufacturers advise avoiding the use ... |
| Erythromycin | SEVERE | Both Amiodarone and Erythromycin prolong the QT interval. Most manufacturers advise avoiding the ... |
| Escitalopram | SEVERE | Both Amiodarone and Escitalopram prolong the QT interval. Most manufacturers advise avoiding the ... |
| Esmolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Es... |
| Etrasimod | SEVERE | Etrasimod might increase the risk of QT-prolongation when given with Amiodarone. Manufacturer adv... |
| Everolimus | SEVERE | Amiodarone is predicted to increase the exposure to Everolimus. Manufacturer advises monitor and ... |
| Fingolimod | SEVERE | Fingolimod might increase the risk of QT-prolongation when given with Amiodarone. Manufacturer ad... |
| Flecainide | SEVERE | Amiodarone increases the concentration of Flecainide. Manufacturer advises adjust Flecainide dose... |
| Fluconazole | SEVERE | Both Amiodarone and Fluconazole prolong the QT interval. Most manufacturers advise avoiding the u... |
| Fludrocortisone | SEVERE | Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de... |
| Formoterol | SEVERE | Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Fosamprenavir | SEVERE | Fosamprenavir is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Fosphenytoin | SEVERE | Amiodarone is predicted to slightly increase the concentration of Fosphenytoin. Manufacturer advi... |
| Furosemide | SEVERE | Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Glasdegib | SEVERE | Both Amiodarone and Glasdegib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Granisetron | SEVERE | Granisetron is predicted to increase the risk of QT-prolongation when given with Amiodarone. Manu... |
| Haloperidol | SEVERE | Both Amiodarone and Haloperidol prolong the QT interval. Most manufacturers advise avoiding the u... |
| Hydrochlorothiazide | SEVERE | Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Hydrocortisone | SEVERE | Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Hydroflumethiazide | SEVERE | Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Hydroxychloroquine | SEVERE | Both Amiodarone and Hydroxychloroquine prolong the QT interval. Most manufacturers advise avoidin... |
| Hydroxyzine | SEVERE | Both Amiodarone and Hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the u... |
| Ibrutinib | SEVERE | Amiodarone is predicted to increase the exposure to Ibrutinib. Manufacturer advises adjust dose—c... |
| Indacaterol | SEVERE | Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Indapamide | SEVERE | Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Inotuzumab ozogamicin | SEVERE | Both Amiodarone and Inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise avoi... |
| Isoflurane | SEVERE | Both Amiodarone and Isoflurane prolong the QT interval. Most manufacturers advise avoiding the us... |
| Isoprenaline | SEVERE | Isoprenaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Itraconazole | SEVERE | Itraconazole is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Ivabradine | SEVERE | Ivabradine is predicted to increase the risk of torsade de pointes when given with Amiodarone. Ma... |
| Ivosidenib | SEVERE | Both Amiodarone and Ivosidenib prolong the QT interval. Most manufacturers advise avoiding the us... |
| Labetalol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with La... |
| Landiolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with La... |
| Lapatinib | SEVERE | Both Amiodarone and Lapatinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Ledipasvir | SEVERE | Ledipasvir increases the risk of severe bradycardia or heart block when given with Amiodarone. Re... |
| Lenvatinib | SEVERE | Both Amiodarone and Lenvatinib prolong the QT interval. Most manufacturers advise avoiding the us... |
| Levobunolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Le... |
| Levomepromazine | SEVERE | Both Amiodarone and Levomepromazine prolong the QT interval. Most manufacturers advise avoiding t... |
| Lopinavir | SEVERE | Lopinavir is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Mefloquine | SEVERE | Mefloquine is predicted to increase the risk of QT-prolongation when given with Amiodarone. Manuf... |
| Methadone | SEVERE | Both Amiodarone and Methadone prolong the QT interval. Most manufacturers advise avoiding the use... |
| Methylprednisolone | SEVERE | Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Metolazone | SEVERE | Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Metoprolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Me... |
| Mexiletine | SEVERE | Mexiletine is predicted to increase the risk of torsade de pointes when given with Amiodarone. Ma... |
| Mizolastine | SEVERE | Mizolastine is predicted to increase the risk of QT-prolongation when given with Amiodarone. Manu... |
| Moxifloxacin | SEVERE | Both Amiodarone and Moxifloxacin prolong the QT interval. Most manufacturers advise avoiding the ... |
| Nadolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Na... |
| Nebivolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Ne... |
| Neratinib | SEVERE | Amiodarone is predicted to increase the exposure to Neratinib. Manufacturer advises avoid or adju... |
| Nilotinib | SEVERE | Both Amiodarone and Nilotinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Nirmatrelvir | SEVERE | Nirmatrelvir boosted with ritonavir is predicted to increase the concentration of Amiodarone. Man... |
| Olodaterol | SEVERE | Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Ondansetron | SEVERE | Both Amiodarone and Ondansetron prolong the QT interval. Most manufacturers advise avoiding the u... |
| Osilodrostat | SEVERE | Both Amiodarone and Osilodrostat prolong the QT interval. Most manufacturers advise avoiding the ... |
| Osimertinib | SEVERE | Both Amiodarone and Osimertinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Ozanimod | SEVERE | Ozanimod might increase the risk of QT-prolongation when given with Amiodarone. Manufacturer advi... |
| Paclitaxel | SEVERE | Amiodarone is predicted to increase the exposure to Paclitaxel. Manufacturer makes no recommendat... |
| Paliperidone | SEVERE | Both Amiodarone and Paliperidone prolong the QT interval. Most manufacturers advise avoiding the ... |
| Palonosetron | SEVERE | Palonosetron is predicted to increase the risk of QT-prolongation when given with Amiodarone. Man... |
| Panobinostat | SEVERE | Both Amiodarone and Panobinostat prolong the QT interval. Most manufacturers advise avoiding the ... |
| Pasireotide | SEVERE | Both Amiodarone and Pasireotide prolong the QT interval. Most manufacturers advise avoiding the u... |
| Pazopanib | SEVERE | Both Amiodarone and Pazopanib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Pentamidine | SEVERE | Pentamidine (intravenous or intramuscular) might increase the risk of QT-prolongation when given ... |
| Phenytoin | SEVERE | Amiodarone is predicted to slightly increase the concentration of Phenytoin. Manufacturer advises... |
| Pimozide | SEVERE | Both Amiodarone and Pimozide prolong the QT interval. Most manufacturers advise avoiding the use ... |
| Pindolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Pi... |
| Ponesimod | SEVERE | Ponesimod might increase the risk of QT-prolongation when given with Amiodarone. Manufacturer adv... |
| Prednisolone | SEVERE | Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Promethazine | SEVERE | Both Amiodarone and Promethazine prolong the QT interval. Most manufacturers advise avoiding the ... |
| Propafenone | SEVERE | Propafenone is predicted to increase the risk of cardiodepression when given with Amiodarone. Man... |
| Propranolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Pr... |
| Quinine | SEVERE | Both Amiodarone and Quinine prolong the QT interval. Most manufacturers advise avoiding the use o... |
| Quizartinib | SEVERE | Both Amiodarone and Quizartinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Ranolazine | SEVERE | Both Amiodarone and Ranolazine prolong the QT interval. Most manufacturers advise avoiding the us... |
| Ribociclib | SEVERE | Both Amiodarone and Ribociclib prolong the QT interval. Most manufacturers advise avoiding the us... |
| Ritonavir | SEVERE | Ritonavir is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Salbutamol | SEVERE | Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Salmeterol | SEVERE | Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Selpercatinib | SEVERE | Both Amiodarone and Selpercatinib prolong the QT interval. Most manufacturers advise avoiding the... |
| Sevoflurane | SEVERE | Both Amiodarone and Sevoflurane prolong the QT interval. Most manufacturers advise avoiding the u... |
| Simvastatin | SEVERE | Amiodarone increases the exposure to Simvastatin. Manufacturer advises adjust Simvastatin dose. |
| Siponimod | SEVERE | Siponimod might increase the risk of QT-prolongation when given with Amiodarone. Manufacturer adv... |
| Sirolimus | SEVERE | Amiodarone is predicted to increase the concentration of Sirolimus. Manufacturer makes no recomme... |
| Sofosbuvir | SEVERE | Sofosbuvir is predicted to increase the risk of severe bradycardia or heart block when given with... |
| Sorafenib | SEVERE | Both Amiodarone and Sorafenib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Sotalol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with So... |
| Sunitinib | SEVERE | Both Amiodarone and Sunitinib prolong the QT interval. Most manufacturers advise avoiding the use... |
| Tacrolimus | SEVERE | Amiodarone is predicted to increase the concentration of Tacrolimus. Manufacturer makes no recomm... |
| Talazoparib | SEVERE | Amiodarone is predicted to slightly increase the exposure to Talazoparib. Manufacturer advises av... |
| Terbutaline | SEVERE | Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Tetrabenazine | SEVERE | Both Amiodarone and Tetrabenazine prolong the QT interval. Most manufacturers advise avoiding the... |
| Theophylline | SEVERE | Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Ticagrelor | SEVERE | Amiodarone is predicted to increase the exposure to Ticagrelor. Manufacturer advises use with cau... |
| Timolol | SEVERE | Amiodarone is predicted to increase the risk of cardiovascular adverse effects when given with Ti... |
| Tinzaparin | SEVERE | Amiodarone might increase the risk of hepatotoxicity when given with Tinzaparin (high-dose). Manu... |
| Tolterodine | SEVERE | Both Amiodarone and Tolterodine prolong the QT interval. Most manufacturers advise avoiding the u... |
| Topotecan | SEVERE | Amiodarone is predicted to increase the exposure to Topotecan. Manufacturer advises monitor. |
| Torasemide | SEVERE | Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Toremifene | SEVERE | Both Amiodarone and Toremifene prolong the QT interval. Most manufacturers advise avoiding the us... |
| Triamcinolone | SEVERE | Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Vamorolone | SEVERE | Vamorolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Vandetanib | SEVERE | Both Amiodarone and Vandetanib prolong the QT interval. Most manufacturers advise avoiding the us... |
| Vardenafil | SEVERE | Both Amiodarone and Vardenafil prolong the QT interval. Most manufacturers advise avoiding the us... |
| Vemurafenib | SEVERE | Both Amiodarone and Vemurafenib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Venetoclax | SEVERE | Amiodarone is predicted to increase the exposure to Venetoclax. Manufacturer advises avoid or mon... |
| Verapamil | SEVERE | Amiodarone is predicted to increase the risk of cardiodepression when given with Verapamil. Manuf... |
| Vilanterol | SEVERE | Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Vinblastine | SEVERE | Amiodarone might increase the exposure to Vinblastine. Manufacturer makes no recommendation. |
| Vincristine | SEVERE | Amiodarone might increase the exposure to Vincristine. Manufacturer makes no recommendation. |
| Vindesine | SEVERE | Amiodarone might increase the exposure to Vindesine. Manufacturer makes no recommendation. |
| Vinorelbine | SEVERE | Amiodarone might increase the exposure to Vinorelbine. Manufacturer makes no recommendation. |
| Voclosporin | SEVERE | Both Amiodarone and Voclosporin prolong the QT interval. Most manufacturers advise avoiding the u... |
| Voriconazole | SEVERE | Both Amiodarone and Voriconazole prolong the QT interval. Most manufacturers advise avoiding the ... |
| Warfarin | SEVERE | Amiodarone increases the anticoagulant effect of Warfarin. Manufacturer advises monitor INR. |
| Xipamide | SEVERE | Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointe... |
| Afatinib | MODERATE | Amiodarone is predicted to increase the exposure to Afatinib. Manufacturer advises separating adm... |
| Agalsidase alfa | MODERATE | Amiodarone is predicted to decrease the effects of Agalsidase alfa. Manufacturer advises avoid. |
| Agalsidase beta | MODERATE | Amiodarone is predicted to decrease the effects of Agalsidase beta. Manufacturer advises avoid. |
| Alitretinoin | MODERATE | Amiodarone is predicted to increase the exposure to Alitretinoin. Manufacturer advises adjust Ali... |
| Apixaban | MODERATE | Amiodarone is predicted to increase the exposure to Apixaban. Manufacturer makes no recommendation. |
| Atorvastatin | MODERATE | Amiodarone is predicted to increase the exposure to Atorvastatin. Manufacturer advises monitor an... |
| Avatrombopag | MODERATE | Amiodarone is predicted to increase the exposure to Avatrombopag. Manufacturer advises adjust Ava... |
| Bictegravir | MODERATE | Amiodarone is predicted to increase the exposure to Bictegravir. Manufacturer advises use with ca... |
| Cimetidine | MODERATE | Cimetidine increases the exposure to Amiodarone. Manufacturer makes no recommendation. |
| Clarithromycin | MODERATE | Clarithromycin is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Erlotinib | MODERATE | Amiodarone is predicted to increase the exposure to Erlotinib. Manufacturer advises caution. |
| Fentanyl | MODERATE | Amiodarone is predicted to increase the concentration of Fentanyl. Manufacturer advises monitor a... |
| Fexofenadine | MODERATE | Amiodarone is predicted to increase the exposure to Fexofenadine. Manufacturer makes no recommend... |
| Fidaxomicin | MODERATE | Amiodarone is predicted to increase the exposure to Fidaxomicin. Manufacturer advises avoid. |
| Fluvastatin | MODERATE | Amiodarone is predicted to increase the exposure to Fluvastatin. Manufacturer advises caution. |
| Gilteritinib | MODERATE | Amiodarone is predicted to increase the exposure to Gilteritinib. Manufacturer advises caution or... |
| Glibenclamide | MODERATE | Amiodarone is predicted to increase the exposure to Glibenclamide. Manufacturer makes no recommen... |
| Gliclazide | MODERATE | Amiodarone is predicted to increase the exposure to Gliclazide. Manufacturer makes no recommendat... |
| Glimepiride | MODERATE | Amiodarone is predicted to increase the exposure to Glimepiride. Manufacturer makes no recommenda... |
| Glipizide | MODERATE | Amiodarone is predicted to increase the exposure to Glipizide. Manufacturer makes no recommendation. |
| Grapefruit | MODERATE | Grapefruit juice increases the exposure to Amiodarone. Manufacturer advises avoid. |
| Idelalisib | MODERATE | Idelalisib is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Ketoconazole | MODERATE | Ketoconazole is predicted to increase the exposure to Amiodarone. Manufacturer advises avoid. |
| Letermovir | MODERATE | Letermovir is predicted to increase the concentration of Amiodarone. Manufacturer advises monitor. |
| Levothyroxine | MODERATE | Amiodarone is predicted to increase the risk of thyroid dysfunction when given with Levothyroxine... |
| Liothyronine | MODERATE | Amiodarone is predicted to increase the risk of thyroid dysfunction when given with Liothyronine.... |
| Lomitapide | MODERATE | Amiodarone is predicted to increase the exposure to Lomitapide. Manufacturer advises separate adm... |
| Macitentan | MODERATE | Amiodarone is predicted to increase the exposure to Macitentan. Manufacturer advises caution depe... |
| Mavacamten | MODERATE | Amiodarone is predicted to increase the exposure to Mavacamten. Manufacturer advises monitor and ... |
| Naldemedine | MODERATE | Amiodarone is predicted to increase the exposure to Naldemedine. Manufacturer advises monitor. |
| Nintedanib | MODERATE | Amiodarone is predicted to increase the exposure to Nintedanib. Manufacturer advises monitor. |
| Pibrentasvir | MODERATE | Amiodarone is predicted to increase the exposure to Pibrentasvir. Manufacturer makes no recommend... |
| Pralsetinib | MODERATE | Amiodarone is predicted to increase the exposure to Pralsetinib. Manufacturer makes no recommenda... |
| Relugolix | MODERATE | Amiodarone is predicted to increase the exposure to Relugolix. Manufacturer advises avoid or take... |
| Rimegepant | MODERATE | Amiodarone is predicted to increase the exposure to Rimegepant. Manufacturer advises avoid anothe... |
| Rivaroxaban | MODERATE | Amiodarone might increase the exposure to Rivaroxaban. Manufacturer advises caution in renal impa... |
| Tolbutamide | MODERATE | Amiodarone is predicted to increase the exposure to Tolbutamide. Manufacturer makes no recommenda... |
| Trametinib | MODERATE | Amiodarone is predicted to increase the concentration of Trametinib. Manufacturer advises caution. |
| Velpatasvir | MODERATE | Amiodarone is predicted to increase the concentration of Velpatasvir. Manufacturer advises avoid ... |
| Tigecycline | MILD | Amiodarone might increase the exposure to Tigecycline. Manufacturer makes no recommendation. |
| Acitretin | LOW | Both Amiodarone and Acitretin can increase the risk of hepatotoxicity. |
| Alectinib | LOW | Both Amiodarone and Alectinib can increase the risk of bradycardia. |
| Alfentanil | LOW | Both Amiodarone and Alfentanil can increase the risk of bradycardia. |
| Anidulafungin | LOW | Both Amiodarone and Anidulafungin can increase the risk of hepatotoxicity. |
| Apraclonidine | LOW | Both Amiodarone and Apraclonidine can increase the risk of bradycardia. |
| Asparaginase | LOW | Both Amiodarone and Asparaginase can increase the risk of hepatotoxicity. |
| Bexarotene | LOW | Both Amiodarone and Bexarotene can increase the risk of hepatotoxicity. |
| Bortezomib | LOW | Both Amiodarone and Bortezomib can increase the risk of peripheral neuropathy. |
| Brigatinib | LOW | Both Amiodarone and Brigatinib can increase the risk of bradycardia. |
| Brimonidine | LOW | Both Amiodarone and Brimonidine can increase the risk of bradycardia. |
| Cabazitaxel | LOW | Both Amiodarone and Cabazitaxel can increase the risk of peripheral neuropathy. |
| Capecitabine | LOW | Both Amiodarone and Capecitabine can increase the risk of hepatotoxicity. |
| Carboplatin | LOW | Both Amiodarone and Carboplatin can increase the risk of peripheral neuropathy. |
| Carmustine | LOW | Both Amiodarone and Carmustine can increase the risk of hepatotoxicity. |
| Caspofungin | LOW | Both Amiodarone and Caspofungin can increase the risk of hepatotoxicity. |
| Cisplatin | LOW | Both Amiodarone and Cisplatin can increase the risk of peripheral neuropathy. |
| Clofarabine | LOW | Both Amiodarone and Clofarabine can increase the risk of hepatotoxicity. |
| Clonidine | LOW | Both Amiodarone and Clonidine can increase the risk of bradycardia. |
| Crisantaspase | LOW | Both Amiodarone and Crisantaspase can increase the risk of hepatotoxicity. |
| Cytarabine | LOW | Both Amiodarone and Cytarabine can increase the risk of hepatotoxicity. |
| Dactinomycin | LOW | Both Amiodarone and Dactinomycin can increase the risk of hepatotoxicity. |
| Decitabine | LOW | Both Amiodarone and Decitabine can increase the risk of hepatotoxicity. |
| Demeclocycline | LOW | Both Amiodarone and Demeclocycline can increase the risk of hepatotoxicity. |
| Docetaxel | LOW | Both Amiodarone and Docetaxel can increase the risk of peripheral neuropathy. |
| Donepezil | LOW | Both Amiodarone and Donepezil can increase the risk of bradycardia. |
| Doxycycline | LOW | Both Amiodarone and Doxycycline can increase the risk of hepatotoxicity. |
| Enfuvirtide | LOW | Both Amiodarone and Enfuvirtide can increase the risk of peripheral neuropathy. |
| Eravacycline | LOW | Both Amiodarone and Eravacycline can increase the risk of hepatotoxicity. |
| Fludarabine | LOW | Both Amiodarone and Fludarabine can increase the risk of hepatotoxicity. |
| Fluorouracil | LOW | Both Amiodarone and Fluorouracil can increase the risk of hepatotoxicity. |
| Flutamide | LOW | Both Amiodarone and Flutamide can increase the risk of hepatotoxicity. |
| Galantamine | LOW | Both Amiodarone and Galantamine can increase the risk of bradycardia. |
| Gemcitabine | LOW | Both Amiodarone and Gemcitabine can increase the risk of hepatotoxicity. |
| Heparin | LOW | Both Amiodarone and Heparin can increase the risk of hepatotoxicity. |
| Isoniazid | LOW | Both Amiodarone and Isoniazid can increase the risk of hepatotoxicity. |
| Isotretinoin | LOW | Both Amiodarone and Isotretinoin can increase the risk of hepatotoxicity. |
| Lamivudine | LOW | Both Amiodarone and Lamivudine can increase the risk of peripheral neuropathy. |
| Leflunomide | LOW | Both Amiodarone and Leflunomide can increase the risk of peripheral neuropathy. |
| Lenalidomide | LOW | Both Amiodarone and Lenalidomide can increase the risk of hepatotoxicity. |
| Lymecycline | LOW | Both Amiodarone and Lymecycline can increase the risk of hepatotoxicity. |
| Mercaptopurine | LOW | Both Amiodarone and Mercaptopurine can increase the risk of hepatotoxicity. |
| Methotrexate | LOW | Both Amiodarone and Methotrexate can increase the risk of hepatotoxicity. |
| Metronidazole | LOW | Both Amiodarone and Metronidazole can increase the risk of peripheral neuropathy. |
| Micafungin | LOW | Both Amiodarone and Micafungin can increase the risk of hepatotoxicity. |
| Minocycline | LOW | Both Amiodarone and Minocycline can increase the risk of hepatotoxicity. |
| Nelarabine | LOW | Both Amiodarone and Nelarabine can increase the risk of hepatotoxicity. |
| Neostigmine | LOW | Both Amiodarone and Neostigmine can increase the risk of bradycardia. |
| Nevirapine | LOW | Both Amiodarone and Nevirapine can increase the risk of hepatotoxicity. |
| Nicotinic acid | LOW | Both Amiodarone and Nicotinic acid can increase the risk of hepatotoxicity. |
| Nitrofurantoin | LOW | Both Amiodarone and Nitrofurantoin can increase the risk of peripheral neuropathy. |
| Oxaliplatin | LOW | Both Amiodarone and Oxaliplatin can increase the risk of peripheral neuropathy. |
| Oxandrolone | LOW | Both Amiodarone and Oxandrolone can increase the risk of hepatotoxicity. |
| Oxymetholone | LOW | Both Amiodarone and Oxymetholone can increase the risk of hepatotoxicity. |
| Oxytetracycline | LOW | Both Amiodarone and Oxytetracycline can increase the risk of hepatotoxicity. |
| Paracetamol | LOW | Both Amiodarone and Paracetamol can increase the risk of hepatotoxicity. |
| Pegaspargase | LOW | Both Amiodarone and Pegaspargase can increase the risk of hepatotoxicity. |
| Pemetrexed | LOW | Both Amiodarone and Pemetrexed can increase the risk of hepatotoxicity. |
| Pomalidomide | LOW | Both Amiodarone and Pomalidomide can increase the risk of hepatotoxicity. |
| Pravastatin | LOW | Both Amiodarone and Pravastatin can increase the risk of hepatotoxicity. |
| Propofol | LOW | Both Amiodarone and Propofol can increase the risk of bradycardia. |
| Pyrazinamide | LOW | Both Amiodarone and Pyrazinamide can increase the risk of hepatotoxicity. |
| Pyridostigmine | LOW | Both Amiodarone and Pyridostigmine can increase the risk of bradycardia. |
| Remifentanil | LOW | Both Amiodarone and Remifentanil can increase the risk of bradycardia. |
| Rivastigmine | LOW | Both Amiodarone and Rivastigmine can increase the risk of bradycardia. |
| Rosuvastatin | LOW | Both Amiodarone and Rosuvastatin can increase the risk of hepatotoxicity. |
| Selegiline | LOW | Both Amiodarone and Selegiline can increase the risk of bradycardia. |
| Sotorasib | LOW | Both Amiodarone and Sotorasib can increase the risk of hepatotoxicity. |
| Streptozocin | LOW | Both Amiodarone and Streptozocin can increase the risk of hepatotoxicity. |
| Sufentanil | LOW | Both Amiodarone and Sufentanil can increase the risk of bradycardia. |
| Suxamethonium | LOW | Both Amiodarone and Suxamethonium can increase the risk of bradycardia. |
| Teriflunomide | LOW | Both Amiodarone and Teriflunomide can increase the risk of peripheral neuropathy. |
| Testosterone | LOW | Both Amiodarone and Testosterone can increase the risk of hepatotoxicity. |
| Tetracycline | LOW | Both Amiodarone and Tetracycline can increase the risk of hepatotoxicity. |
| Thalidomide | LOW | Both Amiodarone and Thalidomide can increase the risk of bradycardia. |
| Tioguanine | LOW | Both Amiodarone and Tioguanine can increase the risk of hepatotoxicity. |
| Tizanidine | LOW | Both Amiodarone and Tizanidine can increase the risk of bradycardia. |
| Trabectedin | LOW | Both Amiodarone and Trabectedin can increase the risk of hepatotoxicity. |
| Valproate | LOW | Both Amiodarone and Valproate can increase the risk of hepatotoxicity. |
| Vitamin A | LOW | Both Amiodarone and Vitamin A can increase the risk of hepatotoxicity. |
| Vorasidenib | LOW | Both Amiodarone and Vorasidenib can increase the risk of hepatotoxicity. |
| Zidovudine | LOW | Both Amiodarone and Zidovudine can increase the risk of hepatotoxicity. |
Check Amiodarone against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker